Oxybutynin
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Oxybutynin: From Overactive Bladder to Restless Legs Syndrome
One-Sentence Summary
Oxybutynin is an antimuscarinic (M3 receptor antagonist) drug that acts on smooth muscle spasm and bladder detrusor muscle, generally used for bladder-related conditions such as overactive bladder. The TxGNN model predicts it may be effective for Restless Legs Syndrome, but currently no clinical trials and no supporting literature exist for this prediction, and the model’s own mechanistic rationale finds no plausible biological link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in this evidence pack (data gap); Oxybutynin’s known pharmacology is antimuscarinic action on bladder smooth muscle/detrusor overactivity |
| Predicted New Indication | Restless Legs Syndrome |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, structured mechanism of action (MOA) data is not available in this evidence pack — this is flagged as a High-severity data gap (DG002). However, the evidence pack’s own repurposing rationale describes Oxybutynin as an antimuscarinic drug (M3 receptor antagonist) that acts on smooth muscle spasm and bladder detrusor muscle, consistent with its established general use in bladder-related conditions.
Restless Legs Syndrome (RLS) has a well-characterised pathophysiology centred on dopaminergic system dysregulation and abnormal brain iron metabolism. These pathways have no known overlap with muscarinic receptor antagonism or bladder smooth muscle activity. The evidence pack’s own mechanistic assessment for this prediction states explicitly that there is no reasonable mechanistic support linking Oxybutynin’s pharmacology to RLS pathology.
The TxGNN score of 99.74% therefore reflects similarity within the knowledge graph embedding space only, not any clinical, preclinical, or mechanistic corroboration. This is a clear case where a high model confidence score should be interpreted with caution rather than taken as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
According to this evidence pack, Oxybutynin currently holds no UK marketing authorisation (0 licences on record; market status: not marketed). No product-level data (marketing authorisation number, product name, dosage form, approved indication) is available to tabulate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: MHRA/SmPC-equivalent warnings and contraindications for this drug are recorded as a Blocking data gap in this evidence pack — DG001 — meaning a formal safety review (S1) cannot yet be completed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on TxGNN embedding similarity (Evidence Level L5), with no clinical trials or literature support, and the evidence pack’s own mechanistic analysis finds no plausible biological link between Oxybutynin’s antimuscarinic action and RLS’s dopaminergic/iron-metabolism pathology. The drug also currently has no UK marketing authorisation on record, and both MOA and SmPC safety data are outstanding data gaps.
To proceed, the following is needed:
- SmPC warnings and contraindications (Blocking data gap, DG001)
- Confirmed mechanism of action documentation (High-severity data gap, DG002)
- Independent mechanistic or preclinical evidence connecting antimuscarinic activity to RLS pathophysiology
- Confirmation of current/planned UK marketing authorisation status for Oxybutynin
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.